Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL DEVICE NEWS IN BRIEF
December 17, 2007
- Re-Pricing Runs Counter to Innovation: Industry
December 17, 2007
- TOPICS／Number of Female MRs Increasing but Their Retention Rates Need Improvement
December 17, 2007
- Council Inaugurated to Promote Development of Vaccines
December 17, 2007
- Pediatric Drugs Adversely Affect Developing Companies
December 17, 2007
- New Rule to Exclude Members Receiving Over \3 Mil. Donations from CDFS Review Process
December 17, 2007
- REGULATORY NEWS IN BRIEF
December 17, 2007
- Geninax Posts \1.9 Bil. Sales in the 1st Month
December 10, 2007
- Clinical Trial Network Created by Six Universities
December 10, 2007
- Half of Physicians Start Osteoporosis Treatment in Patients with Reduced Bone Mass
December 10, 2007
- Ethical Drug Market Up 4.8% in 3rd Qtr; Aricept Surges
December 10, 2007
- Alliances with Overseas Facilities Considered
December 10, 2007
- Astellas to Acquire Agensys Inc.
December 10, 2007
- Takepron Replaces Gaster as No.1 Drug for Ulcers
December 10, 2007
- R&D NEWS IN BRIEF
December 10, 2007
- BUSINESS NEWS IN BRIEF
December 10, 2007
- Nichi-Iko to Prepare Action Program to Enhance Reliability of Generics
December 10, 2007
- NEW PRODUCTS／Mochida: Beselna Cream 5%
December 10, 2007
- JMA Accepts New Prescription Form If Box Is Provided for Each Drug
December 10, 2007
- TOPICS／ACCJ Demands Participation of Foreign-Affiliated Companies in Informatization Process
December 10, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…